DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025" drug pipelines to their offering.
Endometriosis market to grow steadily, surpassing $2 billion by 2025.
The endometriosis market across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from around $1.72 billion in 2015 to just over $2 billion by 2025, representing a compound annual growth rate (CAGR) of 1.7%, according to research.
The latest report states that this modest growth will be driven by increased disease awareness and earlier diagnoses, improvements in non-invasive diagnostic methods, and, most importantly, the launch of elagolix in the US and Europe 2018.
In Japan, the launch of GnRH antagonist relugolix will have a minimal impact on the endometriosis market, with the drug, anticipated to launch in 2021, only contributing 2% towards drug sales in 2025. However, the Japanese market will still undergo sustained growth during the forecast period.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Epidemiology
5 Current Treatment Options
6 Unmet Needs Assessment and Opportunity Analysis
7 Research and Development Strategies
8 Clinical Trial Design
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Appendix
Companies Mentioned
- Pfizer
- Bayer
- Evotec
- AbbVie
- Nobelpharma
- Takeda
- Mochida
- Abbott
- Sanofi
- AstraZeneca
- Astellas Pharma
- Ipsen
- Ferring
- Mitsubishi
- Merck
- Teva
- Barr Laboratories
- Duramed Pharma
- Resource Medical
- Laboratory Biodim
- Rottapharm SL
- Repros
- PregLem
- Nobelpharma
- Gedeon Richter
- Euroscreen
- GlaxoSmithKline
- Nippon Shinyaku
- Forendo Pharma
- ElexoPharm
- Philogen
- ValiRx
- Viteava Pharma
- Dongkook Pharma
- Luye Pharma Group
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/b5cjbk/opportunityanalyze
